Han and Partin reported predictive information for a male with clinically localized prostate cancer. This can help to predict the extent of disease at radical prostatectomy. The authors are from the Johns Hopkins University.
Patient selection: male with clinically localized prostate cancer
Parameters:
(1) T code from T1c to T2c
(2) serum PSA in ng/mL
(3) Gleason score
OC = organ confined
ECE = extracapsular extension
SV = seminal vesicle involvement
T Code |
PSA |
GS |
OC |
ECE |
SV+ |
LN+ |
T1c |
0 to 2.5 |
2 to 4 |
95 |
5 |
0 |
0 |
|
|
5 or 6 |
90 |
9 |
0 |
0 |
|
|
3+4 |
79 |
17 |
2 |
1 |
|
|
4+3 |
71 |
25 |
2 |
1 |
|
|
8 to 10 |
66 |
28 |
4 |
1 |
|
2.6 to 4 |
2 to 4 |
92 |
8 |
0 |
0 |
|
|
5 or 6 |
84 |
15 |
1 |
0 |
|
|
3+4 |
68 |
27 |
4 |
1 |
|
|
4+3 |
58 |
37 |
4 |
1 |
|
|
8 to 10 |
52 |
40 |
6 |
1 |
|
4.1 to 6 |
2 to 4 |
90 |
10 |
0 |
0 |
|
|
5 or 6 |
89 |
19 |
1 |
0 |
|
|
3+4 |
63 |
32 |
3 |
2 |
|
|
4+3 |
52 |
42 |
3 |
3 |
|
|
8 to 10 |
46 |
45 |
5 |
3 |
|
6.1 to 10 |
2 to 4 |
87 |
13 |
0 |
0 |
|
|
5 or 6 |
75 |
23 |
2 |
0 |
|
|
3+4 |
54 |
36 |
8 |
2 |
|
|
4+3 |
43 |
47 |
8 |
2 |
|
|
8 to 10 |
37 |
48 |
13 |
3 |
|
>10 |
2 to 4 |
80 |
20 |
0 |
0 |
|
|
5 or 6 |
62 |
33 |
4 |
2 |
|
|
3+4 |
37 |
43 |
12 |
8 |
|
|
4+3 |
27 |
51 |
11 |
10 |
|
|
8 to 10 |
22 |
50 |
17 |
11 |
T2a |
0 to 2.5 |
2 to 4 |
91 |
9 |
0 |
0 |
|
|
5 or 6 |
81 |
17 |
1 |
0 |
|
|
3+4 |
64 |
29 |
5 |
2 |
|
|
4+3 |
53 |
40 |
4 |
3 |
|
|
8 to 10 |
47 |
42 |
7 |
3 |
|
2.6 to 4 |
2 to 4 |
85 |
15 |
0 |
0 |
|
|
5 or 6 |
71 |
27 |
2 |
0 |
|
|
3+4 |
50 |
41 |
7 |
2 |
|
|
4+3 |
39 |
52 |
6 |
2 |
|
|
8 to 10 |
33 |
53 |
10 |
3 |
|
4.1 to 6 |
2 to 4 |
81 |
19 |
0 |
0 |
|
|
5 or 6 |
66 |
32 |
1 |
1 |
|
|
3+4 |
44 |
46 |
5 |
4 |
|
|
4+3 |
33 |
56 |
5 |
6 |
|
|
8 to 10 |
28 |
58 |
8 |
6 |
|
6.1 to 10 |
2 to 4 |
76 |
24 |
0 |
0 |
|
|
5 or 6 |
58 |
37 |
4 |
1 |
|
|
3+4 |
35 |
49 |
13 |
3 |
|
|
4+3 |
25 |
58 |
11 |
5 |
|
|
8 to 10 |
21 |
57 |
17 |
5 |
|
>10 |
2 to 4 |
65 |
35 |
0 |
0 |
|
|
5 or 6 |
42 |
47 |
6 |
4 |
|
|
3+4 |
20 |
49 |
16 |
14 |
|
|
4+3 |
14 |
55 |
13 |
18 |
|
|
8 to 10 |
11 |
52 |
19 |
17 |
T2b |
0 to 2.5 |
2 to 4 |
88 |
12 |
0 |
0 |
|
|
5 or 6 |
75 |
22 |
2 |
1 |
|
|
3+4 |
54 |
35 |
6 |
4 |
|
|
4+3 |
43 |
45 |
5 |
6 |
|
|
8 to 10 |
37 |
46 |
9 |
6 |
|
2.6 to 4 |
2 to 4 |
80 |
20 |
0 |
0 |
|
|
5 or 6 |
63 |
34 |
2 |
1 |
|
|
3+4 |
41 |
47 |
9 |
3 |
|
|
4+3 |
30 |
57 |
7 |
4 |
|
|
8 to 10 |
25 |
57 |
12 |
5 |
|
4.1 to 6 |
2 to 4 |
75 |
25 |
0 |
0 |
|
|
5 or 6 |
57 |
39 |
2 |
2 |
|
|
3+4 |
35 |
51 |
7 |
7 |
|
|
4+3 |
25 |
60 |
5 |
10 |
|
|
8 to 10 |
21 |
59 |
9 |
10 |
|
6.1 to 10 |
2 to 4 |
69 |
31 |
0 |
0 |
|
|
5 or 6 |
49 |
44 |
5 |
2 |
|
|
3+4 |
26 |
52 |
16 |
6 |
|
|
4+3 |
19 |
60 |
13 |
8 |
|
|
8 to 10 |
15 |
57 |
19 |
8 |
|
>10 |
2 to 4 |
57 |
43 |
0 |
0 |
|
|
5 or 6 |
33 |
52 |
8 |
8 |
|
|
3+4 |
14 |
47 |
17 |
22 |
|
|
4+3 |
9 |
50 |
13 |
27 |
|
|
8 to 10 |
7 |
46 |
19 |
27 |
T2c |
0 to 2.5 |
2 to 4 |
86 |
14 |
0 |
0 |
|
|
5 or 6 |
73 |
24 |
1 |
1 |
|
|
3+4 |
51 |
36 |
5 |
6 |
|
|
4+3 |
39 |
45 |
5 |
9 |
|
|
8 to 10 |
34 |
47 |
8 |
10 |
|
2.6 to 4 |
2 to 4 |
78 |
22 |
0 |
0 |
|
|
5 or 6 |
61 |
36 |
2 |
1 |
|
|
3+4 |
38 |
48 |
8 |
5 |
|
|
4+3 |
27 |
57 |
6 |
7 |
|
|
8 to 10 |
23 |
57 |
10 |
8 |
|
4.1 to 6 |
2 to 4 |
73 |
27 |
0 |
0 |
|
|
5 or 6 |
55 |
40 |
2 |
3 |
|
|
3+4 |
31 |
50 |
6 |
12 |
|
|
4+3 |
21 |
57 |
4 |
16 |
|
|
8 to 10 |
57 |
7 |
16 |
13 |
|
6.1 to 10 |
2 to 4 |
67 |
33 |
0 |
0 |
|
|
5 or 6 |
46 |
46 |
5 |
3 |
|
|
3+4 |
52 |
13 |
10 |
11 |
|
|
4+3 |
58 |
11 |
13 |
7 |
|
|
8 to 10 |
56 |
16 |
13 |
6 |
|
>10 |
2 to 4 |
54 |
46 |
0 |
0 |
|
|
5 or 6 |
30 |
51 |
6 |
13 |
|
|
3+4 |
11 |
42 |
13 |
33 |
|
|
4+3 |
7 |
43 |
10 |
38 |
|
|
8 to 10 |
6 |
41 |
15 |
38 |
Specialty: Hematology Oncology